Sign up to save your podcasts
Or
Share 169 - Sensorion's Quest to Restore, Treat, and Prevent Hearing Loss: Interview with Nawal Ouzren
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
169 - Sensorion's Quest to Restore, Treat, and Prevent Hearing Loss: Interview with Nawal Ouzren
This week, we explore the world of investigational medicines that have the potential to revolutionize the landscape of hearing healthcare, from restoration to treatment and prevention. Our guest for this insightful discussion is Nawal Ouzren, the CEO of the French biotech firm, Sensorion. With a distinguished career that includes significant roles at Shire and Baxter, Ouzren sheds light on Sensorion's mission, centered around three fundamental pillars: addressing hearing loss post-onset, proactive strategies for hearing loss prevention, and developing groundbreaking gene therapies to combat congenital deafness.
Sensorion's lead drug candidate, SENS-401, has shown potential in applications ranging from sudden sensorineural hearing loss, preserving hearing in cochlear implantation surgery, and addressing cisplatin-induced ototoxicity. Additionally, Sensorion is developing promising gene therapies to treat congenital hearing disorders, in collaboration with Institut Pasteur.
For more information about Sensorion, visit the company's website: https://www.sensorion.com/en/
Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn and Twitter.
- https://twitter.com/WeekinHearing
- https://www.linkedin.com/company/this-week-in-hearing
- https://hearinghealthmatters.org/thisweek/
View all episodes
By This Week in Hearing
5
11 ratings
This week, we explore the world of investigational medicines that have the potential to revolutionize the landscape of hearing healthcare, from restoration to treatment and prevention. Our guest for this insightful discussion is Nawal Ouzren, the CEO of the French biotech firm, Sensorion. With a distinguished career that includes significant roles at Shire and Baxter, Ouzren sheds light on Sensorion's mission, centered around three fundamental pillars: addressing hearing loss post-onset, proactive strategies for hearing loss prevention, and developing groundbreaking gene therapies to combat congenital deafness.
Sensorion's lead drug candidate, SENS-401, has shown potential in applications ranging from sudden sensorineural hearing loss, preserving hearing in cochlear implantation surgery, and addressing cisplatin-induced ototoxicity. Additionally, Sensorion is developing promising gene therapies to treat congenital hearing disorders, in collaboration with Institut Pasteur.
For more information about Sensorion, visit the company's website: https://www.sensorion.com/en/
Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn and Twitter.
- https://twitter.com/WeekinHearing
- https://www.linkedin.com/company/this-week-in-hearing
- https://hearinghealthmatters.org/thisweek/
More shows like This Week in Hearing
View all
Pivot
9,140 Listeners
The Daily
111,746 Listeners
The Indicator from Planet Money
9,555 Listeners
Interesting Times with Ross Douthat
6,751 Listeners
The Audiologist
2 Listeners
Hearing Matters Podcast
16 Listeners
The Ezra Klein Show
15,220 Listeners
The Weekly Show with Jon Stewart
10,508 Listeners